AstraZeneca Pharma India Ltd to discontinue the manufacturing and marketing of Imdur from April 1, 2025

AstraZeneca Pharma India Limited will be discontinuing with the manufacturing and marketing of the product Prolonged release Isosorbide-5-mononitrate Tablets BP 30 mg and 60 mg (Imdur) from April 1, 2025.

Imdur is currently being indicated for Prophylactic treatment of angina pectoris.

Shares of AstraZeneca Pharma India Limited was last trading in BSE at Rs. 8493.90 as compared to the previous close of Rs. 8373.75. The total number of shares traded during the day was 1673 in over 727 trades.

The stock hit an intraday high of Rs. 8632.30 and intraday low of 8250.00. The net turnover during the day was Rs. 14201356.00.

Source : Equity Bulls

Keywords

AstraZenecaPharmaIndia INE203A01020 Manufacturing Marketing Discontinue Imdur